Circio Holding ASA (OSL:CRNA) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Circio Holding ASA's Free Cash Flow for the six months ended in Dec. 2024 was kr-21.40 Mil. Circio Holding ASA's Revenue for the six months ended in Dec. 2024 was kr0.00 Mil. Therefore, Circio Holding ASA's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Circio Holding ASA's current FCF Yield % is -75.27%.

The historical rank and industry rank for Circio Holding ASA's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Circio Holding ASA was -1137.77%. The lowest was -413214.81%. And the median was -64093.16%.

OSL:CRNA's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -121.695
* Ranked among companies with meaningful FCF Margin % only.

Circio Holding ASA FCF Margin % Historical Data

The historical data trend for Circio Holding ASA's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA FCF Margin % Chart

Circio Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-17,766.51

-1,137.77

-72,673.98

Circio Holding ASA Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-510.87	-	-24,466.67	-	-

Competitive Comparison of Circio Holding ASA's FCF Margin %

For the Biotechnology subindustry, Circio Holding ASA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Circio Holding ASA's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Circio Holding ASA's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Circio Holding ASA's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Circio Holding ASA FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Circio Holding ASA's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-40.721	/	0
	=	%

Circio Holding ASA's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-21.398	/	0
	=	%

Circio Holding ASA FCF Margin % Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Circio Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0RIS:UK

Address

Saint Olavs plass, Pb. 6887, Oslo, NOR, 0130

Website

https://www.circio.com

Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients. The company's pipeline candidate includes circVec and Mutant KRAS.

Circio Holding ASA Headlines

No Headlines